China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
International Outcry Grows Over Re-Arrest of Nobel Laureate Narges Mohammadi in Iran 
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores 
Federal Judge Declines to Immediately Halt Trump’s $300 Million White House Ballroom Project 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
California, 18 States Sue to Block Trump’s $100,000 H-1B Visa Fee 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Federal Appeals Court Allows Trump’s National Guard Deployment in Washington, D.C. to Continue 
Epstein Files Released by DOJ Spotlight Bill Clinton, Raise Questions Over Trump Mentions 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
U.S. Pressures ICC to Limit Authority as Washington Threatens New Sanctions 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
On Monday, a U.S. appeals court ruled in favor of 3M, E.I. du Pont de Nemours and Co, and other manufacturers of "forever chemicals." The court rejected a lower court's ruling, allowing approximately 11.8 million Ohio residents to sue the companies.
Reuters noted that the ruling relieves considerable legal pressure placed on the chemical manufacturers to settle the plaintiffs' claims.
Court Ruling Questions Class Action Suit's Validity
According to Yahoo, Lead plaintiff Kevin Hardwick's complaint against the manufacturers faced scrutiny from the court. The appeals court found his complaint to be overly broad and lacking evidence that the per- and polyfluoroalkyl substances (PFAS) detected in his body could be directly attributed to the defendants.
The court emphasized that the complaint targeted the collective actions of the companies rather than individual responsibility. Notably, the case involved just 10 out of thousands of companies involved in PFAS manufacturing.
The lower court's approval of the class action suit has been vacated, and the court instructed the dismissal of Hardwick's lawsuit. The lawsuit aimed to hold the companies accountable for the health impacts of PFAS exposure and sought to establish a fund to monitor Ohio residents.
Additionally, Hardwick's request for the companies to fund studies on the health effects of PFAS was denied. These forever chemicals, commonly found in consumer products, have been linked to cancer and other diseases.
Robert Bilott, attorney for Hardwick, expressed disappointment with the court's decision. He stated that it contradicts what is known about the history of PFAS manufacturing in the United States. Bilott's legal team is currently evaluating whether to appeal the ruling further.
The Persistence and Prevalence of Forever Chemicals
PFAS substances earned the nickname "forever chemicals" due to their resistance to breaking down in nature or in the human body. The growing number of lawsuits filed against 3M, DuPont, and other manufacturers in recent years reflect concerns over alleged PFAS contamination.
In June, 3M agreed to pay $10.3 billion to settle hundreds of claims regarding public drinking water pollution caused by PFAS. Furthermore, Chemours Co, DuPont de Nemours Inc, and Corteva reached a similar settlement worth $1.19 billion with U.S. water providers.
Photo: 3M News Center
